Wednesday , 21 October 2015

You are here: Home » Author Archives: Admin

Author Archives: Admin

Pharmaceutical analyst who loves blogging about health and medical issues. Has written more than 150 articles and a book on attention deficit disorder. Correctly predicted delayed approval of Bydureon, approval of Provenge by FDA, and the non-approval of Acthar on June 11.

Can Arthritis Patients Still Take COX-2 Inhibitors?


Millions of people suffer from arthritis and a host of arthritic and rheumatic conditions, which cause a great a deal of pain apart from loss of mobility. While NSAIDs (non-steroid anti-inflammatory drugs) are usually the first line of treatment, COX-2 inhibitors found favor as they had fewer side effects. Conventional painkillers like ibuprofen, paracetamol, aspirin and diclofenac often cause stomach ... Read More »

Novartis’ Serelaxin Gets Breakthrough Therapy Status for Acute Heart Failure

Serelaxin for Acute Heart Failure AHF

The Food and Drug Administration (FDA) has just granted Serelaxin made by Novartis breakthrough designation for acute heart failure. This experimental drug, also called RLX030, has shown promising results in treating symptoms of acute heart failure (AHF) including shortness of breath, congestion and the worsening of heart failure and increasing their life-span as well. Typically patients diagnosed with AHF die ... Read More »

Ibrutinib Under Research as a Breakthrough Oral Drug to Treat Leukamia

Ibrutinib for Leukamia Treatment

Leukemia or blood cancer is of different types. Conventional treatment including chemotherapy, radiotherapy and intracethal chemotherapy wherein the drugs are directly injected into the spinal canal has mixed results, with some people responding and some even going into remission, while in some the disease progresses. Stem cell transplants are sometimes given to patients from donors and the aim of these ... Read More »

What Should You Do If You Are at Risk of Breast Cancer or Have Been Diagnosed With Breast Cancer?

Breast Cancer

Thanks to Angelina Jolie, breast cancer awareness in on the increase since news of her preventive mastectomies made headlines in mainstream press and media. Because her mother died of ovarian cancer, she decided to have herself genetically tested and learnt that she was at 65 percent risk of developing breast cancer and 50 percent risk of developing ovarian cancer as ... Read More »

Stroke Buster Drugs Make News

Stroke buster drugs called tissue plasminogen activators, were first approved by the FDA as far back as 1996. Long term studies on the use and effects of these drugs have shown that while the stroke busting drugs improve the quality of life, they don’t have a marked effect on survival rates. When a stroke is caused by a thrombolytic clot ... Read More »

Xofigo for Prostate Cancer


The Food and Drug Administration has very recently approved a new pharmaceutical, Xofigo, for the treatment of late stage prostate cancer. The drug is a new hope for the treatment of a kind of cancer that affects more than 50% of men over 55 and over 90% of men over 75 years of age. It is intended for men whose ... Read More »

Novel Coronavirus Outbreak in the Mideast

There are periods when certain kinds of outbreaks or infectious diseases gain popularity in the media, even though mankind has never really known a time in the absence of such disease. Several years ago, SARS made a big impression in Europe and the Americas; more recently the various forms of avian and swine flu struck fear in the hearts of ... Read More »

Insomnia and Dual Orexin Receptor Antagonists (Suvorexant)

Insomnia and Dual Orexin Receptor Antagonists - Suvorexant

There has been a breakthrough in the treatment of insomnia. A new compound being tested and prepared for the market blocks a neurotransmitter receptor for orexin (hypocretin), the chemical messenger responsible for arousal and “wakefulness.” Dual orexin receptor antagonists (DORAs) have been shown to improve circadian rhythms and sleep patterns with no side effects, the first drug to do so ... Read More »